TP53 and acute lymphoblastic leukemia: Consistent with this notion, deletions or mutations of p53 [12, 13] or over-expression of Bcl-2 [14, 15] and NF-κB [16] are common in acute myelocytic leukemia (AML) and acute lymphocytic leukemia (ALL) resulting in resistance to drugs that induce apoptosis through the intrinsic pathway.